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ABSTRACT
The purpose of this study was to evaluate the effect of
newly developed selective phosphodiesterase (PDE)
inhibitors, KF19514 (type lilY) and cilostazol (type III),
and theophylline on the secretions of tumor necrosis
factor a (TNFa) and interleukin- 1~ (IL-1~) from human
peripheral monocytes stimulated by lipopolysaccha-
ride (LPS). Human blood monocytes were incubated
with LPS in the absence or presence of KF19514,
cilostazol or theophylline. TNFa and IL-1~ in the cell-
free supernatants were measured with enzyme-linked
immunosorbent assay. KF19514 showed significant
inhibition on the release of TNFa (% inhibition ± SEM
was 82.8 ± 7.4% at 1 urnol/L) and IL-1~ (34.4 ± 7.5%
at 10 umol/L). In addition, KF19514 inhibited the
expression of TNFa mRNA. Cilostazol inhibited the
release of TNFa significantly (60.2 ± 8.9% at 30 urnol/l.)
but not IL-1~. Theophylline inhibited slightly but
significantly the release of TNFa at a therapeutic con-
centration (17.4 ± 5.1 % at 100 urnol/L]. These resuIts
suggest that theophylline may not only have a broncho-
dilating action but also an anti-inflammatory prop-
erty in the treatment of bronchial asthma, and that
KF19514 may have an anti-inflammatory action on at
least the transcriptional level.
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INTRODUCTION
Tumor necrosis factor a (TNFa) and interleukin-1 ~ (IL-1~)
have been found in the broncho-alveolar lavage fluid l-3
and in bronchial biopsy specimens" obtained from
patients with bronchial asthma. These cytokines have a
role in airway inflammation through leukocyte recruit-
ment into the airway by inducing leukocyte adhesion
molecules on endothelial cellss,6 and airway epithelial
cells." Peripheral blood monocytes secrete these cyto-
kines by both irnrnunoloqlcol'' and non-immunological
stimulation, such as that by lipopolysaccharide (LPS).9,lO
Thus, an in vitro system that employs the secretions of
TNFa and IL-1 ~ from LPS-stimulated blood monocytes
could be used to evaluate the anti-inflammatory proper-
ties of anti-asthmatic drugs.
Phosphodiesterase (POE) inhibitors modulate mono-
kine secretion via the elevation of cyclic nucleotides.11- 14
KF 19514 isa newlysynthesized type IIIV dual POE inhibitor.
It is a derivative of KF 17625 and has a more potent bron-
chodilator action than KF17625. 1S ICso values for POE I,
POE II, POE III, POE 1'1, and POE V in vitro have been shown
to be 0.27, > 10, > 10, 0040 and > 10 umol/L, respec-
tively.16 Cilostazol, a derivative of cilostornlde.V:"? is a type
III selective POE lnhibitor./? This drug is clinically used in
Japan for the treatment of obstructive arteriosclerosis.
In this study, we examined the effect of these selective
POE isoenzyme inhibitors on the secretion of TNFa and
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IL-1~ from human peripheral blood monocytes (BMo)
stimulated by LPS. In addition, we evaluated the effect of
theophylline.
METHODS
Reagents and culture materials
Complete medium (MEM) consisted of alpha-modified
Eagle's medium + 1% fetal calf serum + penicillin (100
units/mL) + streptomycin (100 1l9/mLi all from Gibco,
Paisley, UK). KF19514, 5-phenyl-3-(3-pyridyl)methyl-3H-
imidazo[4,5-C][l,8] naphthyridin-4(5H)-one was donated
by Kyowa Hakko Kogyo, Shizuoka, Japan. Cilostazol,
6-(4-[1-cyclohexyl-1 H-tetrazol-5-yl] butoxy)-3,4-dihydro-
2(1 H)-quinolinone was donated by Otsuka Pharmaceutical
company Ltd, Osaka, Japan. Theophylline was obtained
from Sigma (St Louis, MO, USA). KF19514 and theo-
phylline were dissolved in phosphate buffered saline
(PBSi Gibco), whereas cilostazol was dissolved in N,N-
Dimethylformamide (Gibco) and further diluted by
adding MEM to the stock solution.
Isolation of blood monocytes
Blood monocytes were purified by cdherence.? In brief,
blood was drawn from normal volunteers and mono-
nuclear cells (MNC) were obtained by Ficoll-Hypaque
centrifugation (LSM, Organon Teknika Corp, NC, USA).
The concentration of BMo was adjusted to 4 X 10s/mL
using non-specific esterase staining (Sigma) for MNC.
Following this, 1 mL of cell suspension was poured into
culture wells and incubated (3JOC, 5% CO2) for 1 h in
order for BMo to adhere to the bottom of the well. After
the incubation, non-adherent cells were removed by
washing three times with PBS to purify the BMo. Trypan
blue dye exclusion showed 100% viability of the cells
before incubation.
Time course of secretion of TNFa and IL-1~
by lipopolysaccharide stimulation
For the time course study, 400 000 BMo, purified as
described above, were incubated in the absence and
presence of 1 uq/rnl, LPS from Escherichia coli (serotype
026:B6, Sigma) for 0, 2, 6, 12 and 18 h in two subjects.
The supernatant was harvested after centrifugation
(6009, 10 min) at each incubation time and frozen at
-20°C until the assay was undertaken.
Blood monocytes stimulation
A total of 400 000 BMo were incubated in the absence
and presence of 1 Ilg/mL LPS with or without KF19514,
cilostazol or theophylline at the following concentrations:
KF19514 at 1, 10 and 100 urnol/L: cilostazol at 1, 10
and 30 urnol/L: and theophylline at 10, 100 and 1000
umol/L. After 18 h incubation (3JOC, 5% CO2) , the super-
natant was harvested after centrifugation and frozen at
-20°C until the assay was undertaken.
In order to verify that KF19514, cilostazol or theophyl-
line did not influence the cell viability during the incuba-
tion, colorimetric ossov?' using tetrazolium compound,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (Sigma), was performed. There was no difference
in cell viability among these conditions.
Measurement of TNFa and IL-l ~
TNFa and IL-1~ were assayed with an enzyme linked
immunosorbent assay using human TNFa and IL-1~ kits
(Otsuka Pharmaceutical Company, Osaka, Japan). The
assay procedure is briefly described as follows: the
monoclonal antibody specific for each cytokine is
coated onto the microtiter plate provided in the kit.
Standards with known amounts of the cytokine and
samples are pipetted into the wells and left at 4°C for
24 h. After washing, an enzyme-linked polyclonal anti-
body specific to the cytokine is added to the wells and
left at room temperature for 2 h. Following a wash to
remove any unbound antibody-enzyme reagent, a sub-
strate solution is added to the wells and the intensity of
the color is measured by densitometry. A curve is pre-
pared as a standard and, by comparing the optical
density of the samples to this curve, the concentration of
the cytokine in the sample is determined.
Northern analysis
In order to evaluate whether KF19514 inhibits the
expression of TNFa mRNA, Northern analysis 22 was
performed. Ten million BMo were cultured in large
wells under the following conditions: MEM only, MEM +
LPS (1 uq/rnl), and MEM + LPS (1 uq/rnl) + KF19514
(100 urnol/L). After 2 h incubation, the cells in each well
were denatured with guanidine isothiocyanate and RNA
was purified by phenol-chloroforrn.P After electropho-
resis, the RNA was transferred to nitrocellulose filters.
The filters were hybridized with human TNF eDNA probe
SUPPRESSION OF MONOKINE BY POE INHIBITOR 221
RESULTS
Time course of secretion of TNFa and IL-l ~
from LPS-stimulated BMo
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As shown in Fig. 3, KF19514 also inhibited the secretion
of IL-1~ from BMo dose-dependently. The mean of the
Effects of KF19514, cilostazol and
theophyll ine on the secretion of IL-1~
from LPS-stimulated BMo
Effects of KF19514, cilostazol and
theophylline on the secretion of TNFa
from LPS-stimulated BMo
As shown in Fig. 2, KF19514, cilostazol and theophyl-
line dose-dependently inhibited the secretion of TNFa
from LPS-stimulated BMo. The mean of the actual
amount of TNFa secreted after 18 h-stimulation by LPS
was 693 ± 84 pg/mL. ICso values of each agent were as
follows: KF19514, < 1 umol/L: cilostazol, 28/-lmol/L;
theophylline, > 100 umol/L. Thus, KF19514 had the
most potent inhibitory action. Although theophylline
showed the least inhibitory effect on a molar basis, a
significant inhibition was observed at 100 umol/L of
theophylline, which is in the upper range of the thera-
peutic concentration (18 /-lg/mL).
2355 pg/mL for IL-1 ~ in subject 1, and 189 pg/mL and
598.5 pg/mL in subject 2.
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The secretions of TNFa and IL-1~ from LPS-stimulated
BMo were evaluated after 0, 2, 6, 12 and 18 h of incu-
bation. Neither cytokine was detected at any period
without LPS-stimulation. As shown in Fig. 1, the patterns
of secretions for TNFa and IL-1 ~ were different from
each other. Thus, 40% of the maximal secretion ob-
tained at 18 h culture was noted at 2 h for TNFa,
whereas the secretion of IL-1~ was not detected at 2 h
incubation. However, the maximum level of secretion for
both cytokines was observed by 12 h culture and
remained at a plateau for up to 18 h. The means of
the actual amount of the cytokines secreted after 18 h
stimulation by LPS were 524.5 pg/mL for TNFa and
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Statistical analysis
The paired two-tailed Student's t-test was performed for
statistical analysis. Differences were considered significant
for P < 0.05. Values are indicated as mean ± SEM.
(820 bp EcoRI fragment of TNFa cloned in a pUC
vector}" labeled with [32P]dCTP (Amersham, UK) by nick
translation and the hybridized signals were detected by
autoradiography.
Fig. 1 Time course of secretion of TNFa (0) and IL-l ~ (.)
from human blood monocytes stimulated by lipopolysaccharide
(LPS). The cytokines in the supernatant obtained after 0,2,6, 12
and 18 h culture were assayed. Each plot is the mean of %secre-
tion of the amount secreted after 18 h culture. Bars show the
ranges of two subjects.
Fig. 2 The effects of theophylline (0; n = 11), cilostazol
(0; n = 6) and KF19514 (~; n = 6) on the secretion of TNFa
from human blood monocytes stimulated by lipopolysaccharide
(LPS). Results are expressed as mean ± SEM of % sec-
retion of TNFa to positive control stimulation. *P < 0.01 and
**P < 0.001 denote significant difference from the control level.
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actua l amount of Il - l psecreted after 18 h stimulation by
lPSwas 1372 ± 191 pg/m l . The ICso value ofKF1 951 4
was 55 umol/ L. However, neither cilostazol nor theo -
phylline showed statistica lly sign ificant inhibition on the
secretion of Il - l Pfrom SMa.
Effect of KF19514 on the expression of the
TNFa gene by LPS-stimuloted BMo
In order to eva luate whet her KF195 14 inh ib its the
expression of TNFa mRNA, we perfo rmed Northern
ana lysis in two sub jects. RNA was obtain ed from
10 million SMa in each of the fo llowing cu ltu re con -
dition s: MEM a lone, M EM con ta in ing lP S, and M EM
con ta ining lPS and KF195 14 (1 00 u rnol / L}. Ten micro -
gra ms of RNA we re obta ined in each cond it ion.
The aut orad iogram fo r TNFa mRNA in the lane
obta ined f rom cells cultured with lPS an d KF195 14
was wea ker than that ob ta ined from cel ls cu ltu red with
LPS. No ge ne express io n was no ted in the lane without
l PS-stimulation. This result indicated that KF195 14
part ial ly inhibited the gene transcription for TNFu. in
the SMa stimu lated by lPS (Fig . 4) .
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Fig . 4 No rthern ana lysis for TNFa RNA extracted from mono-
cyte culture with mediu m a lone (lone 1), with LP5 (lone 2),
with l PS and KF1951 4 (lane 3) and rRNA from calf liver (lane
4), were hybr id ized with hTN FcDNA probe . An equa l amount of
RNA in each lone was con firmed with the assessment of 285
and 185 rRNA stained with ethid ium bromide after electro-
pho resis (Pa nel B). Solid ar rows indicate the pos itions of 185
an d 285 rRNA. Closed ar row head indicates the pos ition of
TNFamRNA.
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Fig . 3 The effects of theophylline (.; n ~ 11), cilostozol Ie ;
n ~ 6) and KF19514 I. ; n ~ 6)) on the secretion of Il - I Pfrom
huma n blood mo nocytes stimula ted by lipopo lysacchar ide
(LPS). Results ar e expressed as me a n ± SEM of % sec retion of
IL- l ~ to positive control stimulation. *P < 0.0 1 and **P < 0 .001
denote sign ificant difference from the contro l leveL
In the present study, we demonstrated that KF195 14 signi-
ficantly inhibited the secretions of both TNFa and Il-l P
from SMa stimula ted by l PS, and that cilostazol and theo-
phylline significantly inhibited the secretion of TNFu., but
not Il - l p, in the same system. In add ition, we showed
that 100 umol/ L of KF 195 14 decreased the TNFu. mRNA
signa l.
The rank order of the inhibitony effect on the secretion
of TNFu. was KF19514 > cilostazol > theophylline.
KF195 14 showed an inhibitony effect on the release of
TNFa similar to that of type IV POE isoenzyme inhibitors,
rolipram,2s-28 nltroquozone." Ro-20-1724,27,28 and CP-
77059.27 When compared with zordoverine.F? a type
III/IV dual POE inhibitor, the inhibitory effect of KF19514
was quite similar. By contrast, cilostazol showed a weaker
inhibitory effect than did KF19514, which was equal to
that of other type III POE isoenzyme inhibitors, namely
cilostornide.i" milrinori." CI-930,26 rnotcpizone" and
SK&F94836.28Thus, it is suggested that in BMo a type IV
POE isoenzyme may have a major role in the regulation
of the secretion of TNFa, and that the type IV POE
inhibitory action of KF19514 may be responsible for the
inhibitory effect on the secretion of TNFa. In addition,
strong inhibition on the secretion of TNFa by KF19514 is
at least partially due to the inhibition on the expression of
TNFa mRNA, which is similar to the effect of rcliprorri."
KF19514 inhibits both POE I and POE I\/, and 70%
inhibition on the secretion of IL-1~ was observed at 100
urnol/L, which is 350 times the ICso for POE I. It has been
reported that the secretion of IL-1~ from LPS-stimulated
MNC is downregulated by cGMp'14 Therefore, one pos-
sible mechanism is that complete inhibition of POE I by
100 umol/l, of KF19514 may downregulate the secretion
of IL-1~ via a possible increase in cGMp, although BMo
contains POE I at a ratio of 1:10 of POE IV30 However, we
can not exclude the possibility that complete inhibition of
POE IV by KF19514 may inhibit the secretion of IL-1~
because rolipram, a cAMP-elevating but not a cGMP-
elevating agent, has been reported to inhibit the secretion
of IL-1~.27
Cilostazol has been generally prescribed for the treat-
ment of obstructive arteriosclerosis in Japan. A recent
study has shown that cilostazol has bronchodilator and
bronchoprotective effects in normal subjects at a serum
concentration of 6.7 urnol/L'" However, all subjects com-
plained of mild to severe headaches at that concentration.
Although, as shown in this study's results, 10 urnol/L of
cilostazol demonstrated a significant inhibition on the
secretion of TNFa from LPS-stimulated BMo, TNFa inhi-
bition by cilostazol is not clinically feasible.
Theophylline inhibited the secretion of TNFa dose-
dependently and a significant inhibition was observed at
100 umol/Lwhich can be converted into a serum concen-
tration of 18 ~g/mL. Thus, our findings suggested that we
may be clinically using the inhibitory action of theophylline
in the treatment of bronchial asthma. Recently, Spatafora
et 0/. reported that 100 umol/Loftheophylline inhibited the
secretion of TNFa from BMo stimulated by LPS.32 Although
their inhibitory rate was much greater than that in the
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present study, they evaluated the inhibitory effect on the
secretion after 2 h stimulation with LPS. Given that, as
shown in the time-course study, the amount of TNFa after
2 h stimulation with LPS is only 40% of the maximal secre-
tion which was observed after 12 h stimulation and lasted
up to 18 h, the greater rate of inhibition in their study may
have resulted from the shorter period of stimulation by LPS.
In conclusion, we showed that 100 umol/L of theo-
phylline had a significant inhibition on the secretion of
TNFa from purified BMo stimulated by LPS. Therefore, we
suggest that theophylline may have not only a broncho-
dilating action but also an anti-inflammatory property
when used in the treatment of bronchial asthma. In addi-
tion, we demonstrated that KF19514 showed a potent
inhibition on the secretion of TNFa and a moderate inhi-
bition on the secretion of IL-1~ from purified BMo stimu-
lated by LPS, and that 100 urnol/L of KF19514 clearly
decreased the TNFa mRNA signal. Therefore, KF19514
may have an anti-inflammatory property, although its
clinical efficacy remains to be studied.
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